News
Seres Therapeutics
MCRB · NASDAQ
$2.31−$0.11 (−4.55%)TodayMarket closed ·
Prev close $2.42
Latest news
- Press releaseGlobe Newswire
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
- NewsVandana Singh
Seres Therapeutics Posts Early Data for Cancer Therapy Complication
- Press releaseGlobe Newswire
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment
- News
Seres Therapeutics To Host July 8 Webcast To Discuss Top-Line Results From A Trial Evaluating SER-155 In Patients With Immune Checkpoint Inhibitor-Related Enterocolitis
- Press releaseGlobe Newswire
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
- Press releaseGlobe Newswire
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
- News
Seres Therapeutics Q1 EPS $(2.08) Misses $(1.88) Estimate, Sales $358.000K
- Press releaseGlobe Newswire
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
- News
Earnings Scheduled For March 12, 2026
- Press releaseGlobe Newswire
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
- Press releaseGlobe Newswire
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseGlobe Newswire
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
Seres Therapeutics Q3 EPS $0.94 Beats $0.67 Estimate, Sales $351.000K Miss $5.875M Estimate
- Press releaseGlobe Newswire
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
- News
Earnings Scheduled For November 5, 2025
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releaseGlobe Newswire
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releaseGlobe Newswire
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
- News
Uncovering Potential: Seres Therapeutics's Earnings Preview
- Press releaseGlobe Newswire
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
- Press releaseGlobe Newswire
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
- Press releaseGlobe Newswire
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
- Press releaseGlobe Newswire
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Press releaseGlobe Newswire
Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025
- Press releaseGlobe Newswire
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach
- Press releaseGlobe Newswire
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
- Press releaseGlobe Newswire
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference
- Press releaseGlobe Newswire
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
- Press releaseGlobe Newswire
Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Press releaseGlobe Newswire
Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024
- Press releaseBusiness Wire
Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé
- Press releaseGlobe Newswire
Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
- Press releaseGlobe Newswire
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, MCRB, LLAP on Behalf of Shareholders
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCRB, PALT, MRO on Behalf of Shareholders
- Press releaseGlobe Newswire
Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Press releaseGlobe Newswire
Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.